Eleven Biotherapeutics, Inc. is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company's product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis. The Company's therapeutic approach is based on the role of cytokines in diseases of the eye, its understanding of the structural biology of cytokines and its ability to design and engineer proteins to modulate the effects of cytokines. The Company is developing EBI-031 as an intravitreal injection for DME and uveitis. In addition to EBI-031, the Company has another product candidate in early preclinical development, which is designed to block vascular endothelial growth factor (VEGF).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:EBIO
- CUSIP: N/A
- Web: www.elevenbio.com
Capitalization:- Market Cap: $38.29 million
- Outstanding Shares: 15,393,000
Average Prices:- 50 Day Moving Avg: $1.51
- 200 Day Moving Avg: $1.83
- 52 Week Range: $1.31 - $5.97
P/E:- Trailing P/E Ratio: 10.430
- Foreward P/E Ratio: Infinity
- P/E Growth: 0.000
Sales & Book Value:- Annual Revenue: $30.18 million
- Price / Sales: 0.80
- Book Value: $1.33 per share
- Price / Book: 1.18
Profitability:- EBIDTA: $8.26 million
- Net Margins: 11.28%
- Return on Equity: 7.73%
- Return on Assets: 3.16%
Debt:- Current Ratio: 6.52%
- Quick Ratio: 6.52%
Misc:- Average Volume: 257,324 shs.
- Beta: 3.37
- Short Ratio: 5.2
Frequently Asked Questions for Eleven Biotherapeutics (NASDAQ:EBIO)
What is Eleven Biotherapeutics' stock symbol?
Eleven Biotherapeutics trades on the NASDAQ under the ticker symbol "EBIO."
How were Eleven Biotherapeutics' earnings last quarter?
Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) posted its quarterly earnings results on Thursday, May, 4th. The company reported ($0.25) EPS for the quarter. The business earned $0.43 million during the quarter. Eleven Biotherapeutics had a return on equity of 7.73% and a net margin of 11.28%. View Eleven Biotherapeutics' Earnings History.
Who are some of Eleven Biotherapeutics' key competitors?
Some companies that are related to Eleven Biotherapeutics include Sierra Oncology (SRRA), ImmuPharma PLC (IMM), Aldeyra Therapeutics (ALDX), Leap Therapeutics (LPTX), Endocyte (ECYT), Intec Pharma (NTEC), Egalet Corporation (EGLT), Verona Pharma Plc (VRP), Rexahn Pharmaceuticals (RNN), Aeglea BioTherapeutics (AGLE), Xenon Pharmaceuticals (XENE), Synthetic Biologics (SYN), Avacta Group Plc (AVCT), Motif Bio PLC (MTFB), Actinium Pharmaceuticals (ATNM), Akari Therapeutics PLC (AKTX), Imprimis Pharmaceuticals (IMMY) and OptiBiotix Health PLC (OPTI).
Who are Eleven Biotherapeutics' key executives?
Eleven Biotherapeutics' management team includes the folowing people:
- Daniel S. Lynch, Chairman of the Board
- Stephen A. Hurly, President, Chief Executive Officer, Director
- John J McCabe, Principal Financial Officer, Principal Accounting Officer
- Glen C. MacDonald Ph.D., Chief Scientific Officer
- Gregory P. Adams Ph.D., Chief Development Officer
- Arthur P. DeCillis M.D., Chief Medical Officer
- Abbie C. Celniker Ph.D., Director
- Paul G. Chaney, Director
- Wendy L. Dixon Ph.D., Director
- Jay S. Duker MD., Director
How do I buy Eleven Biotherapeutics stock?
Shares of Eleven Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Eleven Biotherapeutics' stock price today?
One share of Eleven Biotherapeutics stock can currently be purchased for approximately $1.58.
MarketBeat Community Rating for Eleven Biotherapeutics (NASDAQ EBIO)MarketBeat's community ratings are surveys of what our community members think about Eleven Biotherapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Eleven Biotherapeutics (NASDAQ:EBIO) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | No ratings tracked in the last 12 months. |
| Consensus Rating: | N/A (Score: NaN) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for Eleven Biotherapeutics (NASDAQ:EBIO)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 1/19/2016 | Citigroup Inc. | Downgrade | Buy -> Neutral | | N/A |  |
| 1/18/2016 | Leerink Swann | Downgrade | Outperform -> Market Perform | | N/A | |
(Data available from 7/27/2015 forward)
Earnings History for Eleven Biotherapeutics (NASDAQ:EBIO)Earnings History by Quarter for Eleven Biotherapeutics (NASDAQ EBIO)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/4/2017 | Q1 2017 | | ($0.25) | | $0.43 million | View | Listen | |
| 3/24/2017 | Q4 2016 | ($0.12) | ($0.20) | | $0.83 million | View | N/A | |
| 11/14/2016 | Q3 | ($0.17) | $0.91 | | $28.70 million | View | Listen | |
| 8/12/2016 | Q2 | | ($0.33) | | $0.28 million | View | N/A | |
| 3/24/2016 | Q4 | ($0.32) | ($0.53) | | $0.57 million | View | N/A | |
| 11/4/2015 | Q315 | ($0.44) | ($0.50) | $0.10 million | $0.07 million | View | Listen | |
| 8/13/2015 | Q215 | ($0.43) | ($0.36) | $0.20 million | $0.11 million | View | Listen | |
| 4/30/2015 | Q115 | ($0.57) | ($0.36) | $0.20 million | $0.24 million | View | Listen | |
| 3/4/2015 | Q414 | ($0.33) | ($0.49) | $0.80 million | $0.38 million | View | Listen | |
| 11/13/2014 | Q314 | ($0.45) | ($0.66) | $0.70 million | $0.54 million | View | N/A | |
| 8/13/2014 | Q2 2014 | ($0.47) | ($0.51) | $0.10 million | $0.76 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Eleven Biotherapeutics (NASDAQ:EBIO)Current Year EPS Consensus Estimate: $-1.85 EPS
Dividend History for Eleven Biotherapeutics (NASDAQ:EBIO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Eleven Biotherapeutics (NASDAQ:EBIO)Insider Ownership Percentage: 28.70%
Institutional Ownership Percentage: 9.72%
Insider Trades by Quarter for Eleven Biotherapeutics (NASDAQ:EBIO)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/28/2016 | Abbie Celniker | Director | Sell | 10,031 | $3.00 | $30,093.00 | |
| 9/23/2016 | Ventures Fund 2007 L Flagship | Major Shareholder | Sell | 443,422 | $3.16 | $1,401,213.52 | |
| 9/21/2016 | Ventures Fund Iv L.P Flagship | Major Shareholder | Sell | 322,723 | $3.75 | $1,210,211.25 | |
| 9/20/2016 | Ventures Fund Iv L.P Flagship | Major Shareholder | Sell | 53,917 | $3.39 | $182,778.63 | |
| 9/19/2016 | Ventures Fund Iv L.P Flagship | Major Shareholder | Sell | 9,700 | $3.31 | $32,107.00 | |
| 9/15/2016 | Ventures Fund 2007 L Flagship | Major Shareholder | Sell | 46,692 | $4.18 | $195,172.56 | |
| 9/7/2016 | Ventures Fund 2007 L Flagship | Major Shareholder | Sell | 129,497 | $4.54 | $587,916.38 | |
| 8/15/2016 | John J Mccabe | CFO | Sell | 1,170 | $4.80 | $5,616.00 | |
| 6/27/2016 | Abbie Celniker | CEO | Sell | 10,029 | $2.08 | $20,860.32 | |
| 6/27/2016 | Karen L Tubridy | Insider | Sell | 4,372 | $2.08 | $9,093.76 | |
| 6/13/2016 | Boxer Capital, Llc | Major Shareholder | Sell | 1,042,000 | $2.74 | $2,855,080.00 | |
| 2/16/2016 | John J Mccabe | SVP | Sell | 1,501 | $0.27 | $405.27 | |
| 12/28/2015 | Abbie Celniker | CEO | Sell | 10,155 | $2.85 | $28,941.75 | |
| 12/28/2015 | Eric Steven Furfine | Insider | Sell | 4,652 | $2.85 | $13,258.20 | |
| 5/8/2015 | Jafco Super V3 Investment Limi | Major Shareholder | Sell | 33,400 | $13.23 | $441,882.00 | |
| 2/2/2015 | Jafco Super V3 Investment Limi | Major Shareholder | Sell | 17,900 | $11.62 | $207,998.00 | |
| 1/30/2015 | Jafco Super V3 Investment Limi | Major Shareholder | Sell | 120,000 | $11.62 | $1,394,400.00 | |
| 1/26/2015 | Jafco Super V3 Investment Limi | Major Shareholder | Sell | 6,300 | $11.85 | $74,655.00 | |
| 1/22/2015 | Jafco Super V3 Investment Limi | Major Shareholder | Sell | 6,300 | $11.82 | $74,466.00 | |
| 1/16/2015 | Jafco Super V3 Investment Limi | Major Shareholder | Sell | 6,100 | $12.07 | $73,627.00 | |
| 8/26/2014 | Jafco Super V3 Investment Limi | Major Shareholder | Sell | 2,000 | $11.54 | $23,080.00 | |
| 8/20/2014 | Jafco Super V3 Investment Limi | Major Shareholder | Sell | 1,165 | $11.54 | $13,444.10 | |
| 8/18/2014 | Jafco Super V3 Investment Limi | Major Shareholder | Sell | 2,600 | $11.81 | $30,706.00 | |
| 8/14/2014 | Jafco Super V3 Investment Limi | Major Shareholder | Sell | 2,000 | $11.75 | $23,500.00 | |
| 2/11/2014 | Jafco Super V3 Investment Limi | Major Shareholder | Buy | 219,790 | $10.00 | $2,197,900.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Eleven Biotherapeutics (NASDAQ:EBIO)
Latest Headlines for Eleven Biotherapeutics (NASDAQ:EBIO)
| Source: |
|
| Date | Headline |
|---|
 | Today's Research Report Coverage on Biotech Stocks -- Eleven Biotherapeutics, Egalet, Aevi Genomic Medicine, and ... - PR Newswire (press release)
www.prnewswire.com - July 18 at 7:38 PM |
 | ETFs with exposure to Eleven Biotherapeutics, Inc. : July 13, 2017
finance.yahoo.com - July 13 at 7:26 PM |
 | Eleven Biotherapeutics (EBIO) Presents At 2017 Marcum Microcap Conference - Slideshow
seekingalpha.com - June 20 at 12:38 AM |
 | Eleven Biotherapeutics, Inc. (EBIO) Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - June 13 at 4:04 PM |
| Eleven Biotherapeutics to Present at 2017 Marcum MicroCap Conference
finance.yahoo.com - June 12 at 5:46 PM |
 | Eleven Biotherapeutics (EBIO) to Partner with AstraZeneca (AZN) & National Cancer Institute on Development of ... - StreetInsider.com
www.streetinsider.com - June 6 at 10:16 PM |
| Eleven Biotherapeutics to Collaborate with AstraZeneca and the National Cancer Institute on Development of ViciniumTM in Combination with Durvalumab for the Treatment of Non-Muscle Invasive Bladder Cancer
finance.yahoo.com - June 6 at 5:15 PM |
 | Eleven Biotherapeutics Announces Data and Safety Monitoring Board (DSMB) Recommendation to Continue Phase 3 Registration Trial with Vicinium™ in Non-Muscle Invasive Bladder ...
www.businesswire.com - June 2 at 4:19 PM |
| Eleven Biotherapeutics (EBIO) Report Data & Safety Monitoring Board Recommendation to Continue Phase 3 ... - StreetInsider.com
www.streetinsider.com - June 1 at 5:36 PM |
| Eleven Biotherapeutics (EBIO) Report Data & Safety Monitoring Board Recommendation to Continue Phase 3 ... - StreetInsider.com
www.streetinsider.com - June 1 at 5:36 PM |
| Eleven Biotherapeutics Announces Data and Safety Monitoring Board (DSMB) Recommendation to Continue Phase 3 Registration Trial with Vicinium™ in Non-Muscle Invasive Bladder Cancer Based on Review of Safety and Efficacy Data
finance.yahoo.com - June 1 at 5:36 PM |
| Eleven Biotherapeutics Announces Data and Safety Monitoring Board (DSMB) Recommendation to Continue Phase 3 Registration Trial with Vicinium™ in Non-Muscle Invasive Bladder Cancer Based on Review of Safety and Efficacy Data
finance.yahoo.com - June 1 at 5:36 PM |
| Eleven Biotherapeutics, Inc.: Fading performance but may be making a comeback?
finance.yahoo.com - May 26 at 5:26 PM |
| ETFs with exposure to Eleven Biotherapeutics, Inc. : May 26, 2017
finance.yahoo.com - May 26 at 5:26 PM |
| Eleven Biotherapeutics Continues Expansion of Clinical ... - Business Wire (press release)
www.businesswire.com - May 17 at 4:54 PM |
| Eleven Biotherapeutics Continues Expansion of Clinical Development Team with Appointment of David Brooks, M.D., Ph.D., to Senior Vice President, Clinical Development
finance.yahoo.com - May 17 at 11:06 AM |
| Zacks Investment Research Upgrades Eleven Biotherapeutics Inc (EBIO) to "Hold"
www.americanbankingnews.com - May 16 at 6:26 PM |
| ETFs with exposure to Eleven Biotherapeutics, Inc. : May 15, 2017
finance.yahoo.com - May 15 at 4:39 PM |
| Short Interest in Eleven Biotherapeutics Inc (EBIO) Drops By 11.9%
www.americanbankingnews.com - May 10 at 7:18 AM |
| Eleven Biotherapeutics, Inc. :EBIO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 8, 2017
finance.yahoo.com - May 8 at 4:46 PM |
| Eleven Biotherapeutics Inc (EBIO) Announces Earnings Results
www.americanbankingnews.com - May 8 at 3:36 PM |
| Eleven Biotherapeutics Inc (EBIO) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - May 5 at 7:38 PM |
| Eleven Biotherapeutics (EBIO) Getting Somewhat Positive Media Coverage, Study Shows
www.americanbankingnews.com - May 4 at 5:08 PM |
| Eleven Biotherapeutics Reports First Quarter 2017 Financial Results - Yahoo Finance
finance.yahoo.com - May 4 at 5:01 PM |
| Investor Network: Eleven Biotherapeutics, Inc. to Host Earnings Call
finance.yahoo.com - May 4 at 9:47 AM |
| Eleven Biotherapeutics Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 4 at 9:47 AM |
| ETFs with exposure to Eleven Biotherapeutics, Inc. : May 3, 2017
finance.yahoo.com - May 3 at 4:45 PM |
| Eleven Biotherapeutics to Report First Quarter 2017 Financial Results on Thursday, May 4, 2017 - Yahoo Finance
finance.yahoo.com - April 28 at 11:02 PM |
| Eleven Biotherapeutics to Report First Quarter 2017 Financial Results on Thursday, May 4, 2017
finance.yahoo.com - April 28 at 5:58 PM |
| Somewhat Critical News Coverage Very Unlikely to Affect Eleven Biotherapeutics (EBIO) Stock Price
www.americanbankingnews.com - April 27 at 5:08 PM |
| Eleven Biotherapeutics (EBIO) Given Daily News Sentiment Score of 0.31
www.americanbankingnews.com - April 24 at 5:45 PM |
| ETFs with exposure to Eleven Biotherapeutics, Inc. : April 21, 2017
finance.yahoo.com - April 21 at 4:55 PM |
| Eleven Biotherapeutics (EBIO) Getting Positive News Coverage, Analysis Finds
www.americanbankingnews.com - April 19 at 10:07 AM |
| Eleven Biotherapeutics (EBIO) Receiving Critical Press Coverage, Analysis Finds
www.americanbankingnews.com - April 14 at 7:48 AM |
| Eleven Biotherapeutics (EBIO) Presents New Preclinical Data With ... - StreetInsider.com
www.streetinsider.com - April 4 at 7:07 AM |
| ELEVEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - April 4 at 7:07 AM |
| Eleven Biotherapeutics Presents New Preclinical Data at AACR Supporting the Potential of the Company’s Locally- and Systematically-Administered Drug Candidates
finance.yahoo.com - April 2 at 4:47 PM |
| ELEVEN BIOTHERAPEUTICS, INC. Financials
finance.yahoo.com - March 30 at 5:18 PM |
| Eleven Biotherapeutics (EBIO) to Present New Preclinical Data at AACR
www.streetinsider.com - March 28 at 12:04 PM |
| Eleven Biotherapeutics to Present New Preclinical Data at the American Association for Cancer Research Annual Meeting 2017
finance.yahoo.com - March 27 at 12:05 PM |
| 7:02 am Eleven Biotherapeutics will present preclinical data 'supporting the ongoing development of its locally- and systemically-administered drug candidates' at the AACR Annual Meeting 2017, on April 2
finance.yahoo.com - March 27 at 12:05 PM |
 | Eleven Biotherapeutics (EBIO) Gains Ahead of Q4 Earnings
www.baystreet.ca - March 26 at 4:36 PM |
| Eleven Biotherapeutics Reports Fourth Quarter and Full Year 2016 Financial Results
finance.yahoo.com - March 24 at 9:40 AM |
| Q4 2016 Eleven Biotherapeutics Inc Earnings Release - Time Not Supplied
biz.yahoo.com - March 24 at 9:40 AM |
| ELEVEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition
biz.yahoo.com - March 24 at 9:40 AM |
| Eleven Biotherapeutics Inc (EBIO) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - March 24 at 9:17 AM |
| Eleven Biotherapeutics (EBIO) Presents At Oppenheimer 27th Annual Healthcare Conference
seekingalpha.com - March 22 at 4:59 PM |
| Eleven Biotherapeutics to Report Fourth Quarter and Full Year 2016 Financial Results on Friday, March 24, 2017
finance.yahoo.com - March 22 at 4:59 PM |
| Eleven Biotherapeutics Inc (EBIO) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - March 21 at 7:34 AM |
| Eleven Biotherapeutics to Present at Oppenheimer's 27th Annual Healthcare Conference
finance.yahoo.com - March 20 at 7:44 PM |
Eleven Biotherapeutics (EBIO) Chart for Thursday, July, 27, 2017
